Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 06, 2019 16:01 ET | Source: GT Biopharma, Inc.

GT Biopharma Announces Closing of Private Placement Financing and Provides Business Update

Corporate, preclinical, clinical and regulatory advancements expected to position Company for a transformational 2019 Company on track to report topline Phase 2a data of GTB-1550 this quarter ...
December 20, 2018 08:22 ET | Source: GT Biopharma, Inc.

GT Biopharma, Inc. to Present at Biotech Showcase™ 2019

– Presentation with live audio webcast, Tuesday, January 8, 2019 at 11:30 AM PST – LOS ANGELES, Dec. 20, 2018 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (OTCQB: GTBP and Euronext Paris GTBP.PA) ("GT...
December 06, 2018 08:05 ET | Source: GT Biopharma, Inc.

GT Biopharma Presents Positive Preclinical Data of Tri-specific NK Cell Engager (TriKE) at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition

– Company’s proprietary TriKE product candidates have the potential to serve as a relatively safe, cost-effective, and easy-to-use therapy for refractory/relapsed AML, high-risk MDS and advanced...
November 20, 2018 07:30 ET | Source: GT Biopharma, Inc.

GT Biopharma Announces Presentation of Two Abstracts at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition

LOS ANGELES, Nov. 20, 2018 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (OTCQB: GTBP and Euronext Paris GTBP.PA) ("GT Biopharma" or the "Company"), an immuno-oncology biotechnology company focused on...
November 15, 2018 08:00 ET | Source: GT Biopharma, Inc.

GT Biopharma Reports Third Quarter 2018 Financial Results and Provides Business Update

– Recent corporate, preclinical, clinical and regulatory advancements expected to position Company for a transformational 2019 – – FDA clearance of IND to advance first-in-class TriKE, GTB-3550, into...
November 01, 2018 09:30 ET | Source: GT Biopharma, Inc.

GT Biopharma Receives FDA Clearance to Commence First-in-Human Phase 1 Study of its First-in-Class Tri-Specific Killer Engager (TriKE), GTB-3550, for the Treatment of Acute Myelogenous Leukemia, Myelodysplatic Syndrome and Mastocytosis

LOS ANGELES, Nov. 01, 2018 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (OTCQB: GTBP and Euronext Paris GTBP.PA) ("GT Biopharma" or the "Company"), an immuno-oncology biotechnology company focused on...
December 18, 2017 10:47 ET | Source: GT Biopharma, Inc.

GT Biopharma, Inc. Files Application for NASDAQ Capital Market Listing

WASHINGTON, Dec. 18, 2017 (GLOBE NEWSWIRE) -- GT Biopharma Inc. (OTCQB:GTBP) today announced that the Company has filed an application to list its common stock on the NASDAQ Capital Market. GT...